# Tango Therapeutics Inc. (TNGX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $22.52, market value $3.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Tango Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 70.6×**. Each dollar of revenue is priced at 70.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 8.3×**. The shares trade at 8.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -3.8%** (5-yr avg -18.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -253.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -162.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -29.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -31.0%**. Each dollar of assets produces -31.0% of profit.

## Growth
- **Revenue growth (1 yr): 48.3%** (3-yr 35.9%/yr, 5-yr 52.1%/yr). Revenue grew 48.3% over the last year, against 52.1% a year compounded over five years.
- **EPS growth (1 yr): 26.9%**. Earnings per share rose 26.9%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 16.32** (quick 16.32). Current assets cover the next year's liabilities 16.32 times.
- **Altman Z-score: 44.84**. A Z-score of 44.84 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Tango Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Tango Therapeutics Inc.; the consensus is strong_buy, with an average price target of $45.18 (+101% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 229.7%** (YTD 154.2%, 3-mo 11.4%). The shares are up 229.7% over twelve months including dividends.
- **From 52-week high: -34.5%** (260.3% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 36**. An RSI of 36 is neutral.
- **Beta (1 yr): 1.41** (volatility 101%). Beta of 1.41 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TNGX · Page: https://foliofundamentals.com/stocks/tngx

Not investment advice.